Mechanism of action
Duloxetine selectively inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) at presynaptic terminals in the central nervous system. Unlike tricyclic antidepressants, it has minimal affinity for muscarinic, histaminergic, alpha-adrenergic, dopaminergic, or opioid receptors, which accounts for its more favorable side effect profile.
The dual reuptake inhibition increases synaptic concentrations of both monoamines in key brain regions. Enhanced serotonergic neurotransmission in limbic structures mediates antidepressant and anxiolytic effects. Increased norepinephrine activity in descending inhibitory pain pathways in the spinal cord provides analgesia for neuropathic and musculoskeletal pain conditions.
The analgesic effect is independent of mood improvement and occurs via modulation of pain perception in the dorsal horn. This dual mechanism makes duloxetine particularly effective for conditions where pain and mood symptoms coexist, such as diabetic peripheral neuropathy with comorbid depression.
- Duloxetine is an SNRI with dual FDA approval for depression/anxiety and chronic pain conditions (diabetic neuropathy, fibromyalgia)
- Black box warning for increased suicide risk in patients <24 years with depression during initial treatment
- Contraindicated in severe hepatic impairment and severe renal impairment (CrCl <30); can cause hepatotoxicity
- Cannot be used with MAOIs (14-day washout required) due to serotonin syndrome risk
- Metabolized by CYP1A2 and CYP2D6; fluvoxamine and ciprofloxacin significantly increase levels
- Discontinuation syndrome (dizziness, paresthesias, nausea) occurs with abrupt cessation; always taper gradually
- Increases bleeding risk when combined with NSAIDs, aspirin, or anticoagulants due to impaired platelet function
- Analgesic effects for neuropathic pain appear faster (within 1 week) than antidepressant effects (4-6 weeks)
Indications
Duloxetine is FDA-approved for multiple psychiatric and pain-related conditions:
Psychiatric indications:
- Major depressive disorder (MDD) in adults
- Generalized anxiety disorder (GAD) in adults and children ≥7 years
Pain-related indications:
- Diabetic peripheral neuropathic pain
- Fibromyalgia
- Chronic musculoskeletal pain (including chronic low back pain and osteoarthritis pain)
Other indications:
- Stress urinary incontinence (approved in some countries, not FDA-approved in the US)
The broad spectrum of approved indications reflects the drug's dual mechanism targeting both central mood regulation and pain modulation. Duloxetine is particularly valuable when patients have comorbid depression and chronic pain, as it addresses both conditions simultaneously. Off-label uses include chemotherapy-induced peripheral neuropathy and chronic pelvic pain, though evidence for these applications is still emerging.
Pharmacokinetics
Absorption: Well absorbed orally with a bioavailability of approximately 50% due to first-pass metabolism. Peak plasma concentrations occur 6 hours after dosing. Food delays time to peak but does not significantly affect overall absorption.
Distribution: Highly protein-bound (>90%, primarily to albumin and alpha-1-acid glycoprotein). Volume of distribution is approximately 1640 L, indicating extensive tissue distribution.
Metabolism: Extensively metabolized in the liver via CYP1A2 and CYP2D6 pathways to inactive metabolites. The drug undergoes oxidation followed by conjugation. Genetic polymorphisms in CYP2D6 can affect clearance, with poor metabolizers having higher plasma concentrations.
Elimination: Excreted primarily in urine (70%) and feces (20%) as metabolites; less than 1% is excreted unchanged. The elimination half-life is approximately 12 hours, allowing once or twice daily dosing.
Special populations: Hepatic impairment significantly increases exposure and is contraindicated in severe cases. Renal impairment (CrCl <30 mL/min) also increases exposure and requires dose avoidance. Elderly patients may have reduced clearance. Smokers (CYP1A2 induction) may have lower duloxetine levels.
Adverse effects
Common adverse effects (>10%):
- Nausea (most common, often transient)
- Dry mouth
- Somnolence or insomnia
- Constipation
- Dizziness
- Fatigue
- Decreased appetite
- Hyperhidrosis (excessive sweating)
Serious adverse effects:
Hepatotoxicity: Duloxetine can cause elevations in serum transaminases and rare cases of hepatic failure. Patients with substantial alcohol use or pre-existing liver disease are at higher risk. It is contraindicated in hepatic insufficiency.
Suicide risk: Black box warning for increased suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) with major depressive disorder and other psychiatric disorders, particularly during the initial months of treatment or dose changes.
Serotonin syndrome: Risk increases with concomitant use of other serotonergic agents (SSRIs, MAOIs, triptans, tramadol, St. John's wort). Presents with mental status changes, autonomic instability, and neuromuscular abnormalities.
Bleeding: SNRIs can impair platelet aggregation, increasing bleeding risk, especially when combined with NSAIDs, aspirin, or anticoagulants.
Cardiovascular: Small increases in blood pressure and heart rate. Orthostatic hypotension can occur, particularly in elderly patients.
Hyponatremia: SIADH has been reported, especially in elderly patients and those on diuretics.
Urinary hesitation/retention: Due to noradrenergic effects on bladder sphincter tone.
Sexual dysfunction: Decreased libido, erectile dysfunction, anorgasmia, ejaculatory delay.
Discontinuation syndrome: Abrupt cessation can cause dizziness, nausea, headache, paresthesias, irritability, and flu-like symptoms. Taper gradually over at least 1-2 weeks.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to duloxetine
- Concurrent use or within 14 days of MAOIs (risk of serotonin syndrome)
- Uncontrolled narrow-angle glaucoma (mydriatic effect)
- Severe hepatic impairment
- Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease
Warnings and precautions:
Hepatic monitoring: Obtain baseline liver function tests in patients with risk factors for liver disease. Discontinue if jaundice or evidence of hepatic injury develops.
Suicide monitoring: Close observation is required during initial treatment and after dose changes, particularly in young adults. Provide small quantities to reduce overdose risk.
Activation of mania/hypomania: Screen for bipolar disorder before initiating treatment. SNRIs can precipitate manic episodes in susceptible individuals.
Seizures: Use with caution in patients with seizure disorders, though seizure risk is relatively low.
Bleeding risk: Exercise caution when combining with anticoagulants, antiplatelet agents, or NSAIDs.
Pregnancy: Category C in older classification (now avoided). Limited human data; use only if benefit justifies potential fetal risk. Neonates exposed late in pregnancy may experience complications requiring prolonged hospitalization, respiratory support, and tube feeding.
Breastfeeding: Present in breast milk; consider risk-benefit ratio.
Alcohol use: Avoid alcohol due to increased hepatotoxicity risk. Cases of severe liver injury have occurred in patients with chronic alcohol use.
Glycemic control: May affect glucose regulation in diabetic patients; monitor blood glucose closely, especially when initiating or discontinuing therapy.
Drug interactions
Major interactions:
MAOIs (phenelzine, tranylcypromine, linezolid, methylene blue): Absolute contraindication. Wait at least 14 days after stopping MAOIs before starting duloxetine, and at least 5 days after stopping duloxetine before starting MAOIs. Risk of fatal serotonin syndrome.
Serotonergic agents: Increased serotonin syndrome risk with SSRIs, other SNRIs, tricyclic antidepressants, triptans, tramadol, tryptophan, buspirone, St. John's wort, and amphetamines.
CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): Significantly increase duloxetine levels (up to 6-fold with fluvoxamine). Avoid combination or reduce duloxetine dose substantially.
Thioridazine: Duloxetine inhibits CYP2D6 and can increase thioridazine levels, potentially causing QTc prolongation and ventricular arrhythmias. Contraindicated.
Anticoagulants and antiplatelets: Increased bleeding risk with warfarin, aspirin, clopidogrel, and NSAIDs due to impaired platelet function.
CNS depressants: Additive sedation with alcohol, benzodiazepines, opioids, and sedative antihistamines.
Other interactions:
- CYP2D6 substrates: Duloxetine is a moderate CYP2D6 inhibitor and can increase levels of drugs like metoprolol, desipramine, and atomoxetine
- Smoking: CYP1A2 induction by tobacco smoke can lower duloxetine levels
- Drugs affecting gastric acidity: Antacids may slightly reduce duloxetine absorption but this is not clinically significant
- Tricyclic antidepressants: Duloxetine increases TCA levels via CYP2D6 inhibition; monitor for TCA toxicity
Clinical pearls
Dual benefit in comorbid conditions: Consider duloxetine first-line when patients present with both depression and chronic pain (e.g., diabetic neuropathy with depression, or fibromyalgia with mood symptoms). The drug addresses both conditions through a single mechanism.
Tolerability strategy: Start at lower doses in elderly or sensitive patients. Nausea typically improves after 1-2 weeks; taking with food and gradual titration minimize this effect.
Pain onset vs mood effects: Analgesic effects for neuropathic pain may appear within 1 week, faster than the 4-6 weeks typically required for full antidepressant and anxiolytic effects. This distinction is important when counseling patients about expected timelines.
Hepatic screening: Check baseline ALT/AST in patients with risk factors (alcohol use, viral hepatitis, obesity). Monitor periodically during treatment if risk factors are present.
Discontinuation: Always taper over 1-2 weeks minimum to avoid discontinuation syndrome. Symptoms include dizziness, paresthesias ("brain zaps"), agitation, and nausea. For patients on long-term treatment, slower tapers may be necessary.
Exam comparison points:
- Duloxetine vs venlafaxine: Both are SNRIs, but duloxetine has more balanced 5-HT/NE inhibition at therapeutic doses. Venlafaxine acts primarily as an SSRI at lower doses with NE effects at higher doses. Duloxetine has more FDA pain indications.
- Duloxetine vs pregabalin/gabapentin: For diabetic neuropathy or fibromyalgia, duloxetine is preferred when comorbid depression exists; gabapentinoids are better when sedation is desired or in patients with hepatic impairment.
- Duloxetine vs SSRIs: Duloxetine may be more effective for pain conditions and has better evidence for fibromyalgia than SSRIs.
Urological considerations: While approved in some countries for stress urinary incontinence, the noradrenergic effects can also cause urinary retention in susceptible patients (e.g., elderly men with BPH).
Monitoring parameters: Blood pressure and heart rate (small increases possible), liver function tests if risk factors present, suicidality (especially first 1-2 months), weight, sodium levels in elderly.
Practical prescribing: Enteric-coated capsules should not be opened, crushed, or chewed. Administer with or without food. Morning or evening dosing based on individual tolerability (sedating vs activating effects vary).
Practice questions
1. A 58-year-old woman with type 2 diabetes and major depression presents for follow-up. She reports persistent burning pain in both feet for the past 6 months and low mood. Her HbA1c is 7.2%. Physical examination reveals decreased sensation to light touch in a stocking distribution bilaterally. Which medication would address both her pain and mood symptoms?
2. A 32-year-old man with depression has been taking duloxetine 60 mg daily for 8 weeks with good response. He now reports difficulty urinating and has to strain to empty his bladder. Physical examination reveals a non-tender, non-enlarged prostate. Urinalysis is normal. Which property of duloxetine best explains this adverse effect?
3. A 45-year-old woman is started on duloxetine for fibromyalgia. Two weeks later, she presents to the emergency department with confusion, tremor, diaphoresis, fever, and hyperreflexia. Her medical history includes migraines for which she takes sumatriptan as needed. Vital signs show temperature 39.1°C, pulse 110/min, and blood pressure 160/95 mmHg. What is the most likely diagnosis?
Frequently asked questions
How does duloxetine work?
Duloxetine works by inhibiting the reuptake of both serotonin and norepinephrine in the central nervous system, increasing the availability of these neurotransmitters in synapses. The enhanced serotonergic activity helps treat depression and anxiety, while increased norepinephrine in descending spinal pain pathways provides analgesia for neuropathic and musculoskeletal pain. This dual mechanism explains why duloxetine is effective for both psychiatric conditions and chronic pain syndromes.
What are the side effects of duloxetine?
The most common side effects of duloxetine include nausea (often the most bothersome initially), dry mouth, constipation, dizziness, fatigue, insomnia or drowsiness, and excessive sweating. Serious adverse effects include hepatotoxicity with elevated liver enzymes, increased suicide risk in young adults under 25, serotonin syndrome when combined with other serotonergic drugs, bleeding complications, sexual dysfunction, and hyponatremia especially in elderly patients. Abrupt discontinuation causes withdrawal symptoms including dizziness, paresthesias, and flu-like symptoms.
Is duloxetine a controlled substance?
No, duloxetine is not a controlled substance and has no potential for abuse or dependence. However, it should not be stopped abruptly because discontinuation syndrome can occur, causing withdrawal-like symptoms including dizziness, sensory disturbances, irritability, and nausea. These symptoms reflect physiological adaptation to the drug rather than true addiction, and they resolve with gradual tapering over 1-2 weeks or longer.
What is the difference between duloxetine and sertraline?
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks reuptake of both serotonin and norepinephrine, while sertraline is a selective serotonin reuptake inhibitor (SSRI) that primarily affects only serotonin. Duloxetine is FDA-approved for chronic pain conditions like diabetic neuropathy and fibromyalgia in addition to depression and anxiety, whereas sertraline is approved for depression, anxiety disorders, PTSD, and OCD but not for pain. Duloxetine carries higher hepatotoxicity risk and is contraindicated in liver disease, while sertraline has a better hepatic safety profile.
Can duloxetine be used for anxiety?
Yes, duloxetine is FDA-approved for generalized anxiety disorder (GAD) in both adults and children aged 7 years and older. It is effective for reducing excessive worry, tension, and physical anxiety symptoms. The anxiolytic effect typically takes 4-6 weeks to fully develop, similar to the timeline for antidepressant effects. Duloxetine may be particularly useful when anxiety coexists with chronic pain or depression, as it can address multiple conditions simultaneously.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AX21
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.